image credit: Unsplash

Altimmune ditches nasal COVID vaccine on weak trial data

June 30, 2021


It’s a big disappointment for Altimmune, which said back in February that it was hoping to find a more convenient alternative to injected COVID-19 vaccines – and one which would be stable at room temperature, making distribution and delivery easier.

It had also hoped to demonstrate that nasal delivery would stimulate a mucosal immune response at the point where the virus enters the body, potentially making the one-dose vaccine more effective at blocking transmission.

Read More on Pharmaphorum